Revolution Medicines, Inc. Amortization of Intangible Assets
Revolution Medicines, Inc. (RVMD) reported Amortization of Intangible Assets of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-05
- Revolution Medicines, Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Revolution Medicines, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Revolution Medicines, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $69.00K, a 74.16% decline year-over-year.
- Revolution Medicines, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $300.00K, a 0.00% change year-over-year.
- Revolution Medicines, Inc. amortization of intangible assets for fiscal 2025 was $870.00K, a 18.62% decline from fiscal 2024.
- Revolution Medicines, Inc. amortization of intangible assets for fiscal 2024 was $1.07M, a 0.09% increase from fiscal 2023.
- Revolution Medicines, Inc. amortization of intangible assets for fiscal 2023 was $1.07M, a 0.09% decline from fiscal 2022.
- Revolution Medicines, Inc. amortization of intangible assets for fiscal 2022 was $1.07M, a 0.00% change from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $69.00K derived: sum of 3 quarters · filed 2026-08-05 | $369.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $69.00K derived: sum of 2 quarters · filed 2026-05-06 | $369.00K derived: sum of 3 quarters · filed 2026-05-06 | $669.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $369.00K derived: sum of 2 quarters · filed 2026-02-25 | $669.00K derived: sum of 3 quarters · filed 2026-08-05 | $870.00K 10-K · filed 2026-02-25 | |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-05 | $600.00K derived: sum of 2 quarters · filed 2026-08-05 | $801.00K 10-Q · filed 2025-11-05 | $1.13M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-05 | $500.00K 10-Q · filed 2026-08-05 | $534.00K 10-Q · filed 2025-08-06 | $834.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $267.00K 10-Q · filed 2026-05-06 | $534.00K derived: sum of 2 quarters · filed 2026-05-06 | $834.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.13M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $567.00K derived: sum of 2 quarters · filed 2026-02-25 | $867.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.07M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $300.00K 10-Q · filed 2025-11-05 | $600.00K derived: sum of 2 quarters · filed 2025-11-05 | $802.00K 10-Q · filed 2025-11-05 | $1.13M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-06 | $534.00K 10-Q · filed 2025-08-06 | $834.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.13M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $267.00K 10-Q · filed 2025-05-07 | $534.00K derived: sum of 2 quarters · filed 2026-02-25 | $834.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.13M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $567.00K derived: sum of 2 quarters · filed 2026-02-25 | $867.00K derived: sum of 3 quarters · filed 2026-02-25 | $1.07M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $300.00K 10-Q · filed 2024-11-06 | $600.00K derived: sum of 2 quarters · filed 2024-11-06 | $801.00K 10-Q · filed 2024-11-06 | $1.14M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $300.00K 10-Q · filed 2024-08-07 | $534.00K 10-Q · filed 2024-08-07 | $835.00K derived: sum of 3 quarters · filed 2025-02-26 | $1.14M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $267.00K 10-Q · filed 2024-05-08 | $535.00K derived: sum of 2 quarters · filed 2025-02-26 | $835.00K derived: sum of 3 quarters · filed 2025-02-26 | $1.14M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $568.00K derived: sum of 2 quarters · filed 2025-02-26 | $868.00K derived: sum of 3 quarters · filed 2025-02-26 | $1.07M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $300.00K 10-Q · filed 2023-11-06 | $600.00K derived: sum of 2 quarters · filed 2023-11-06 | $801.00K 10-Q · filed 2023-11-06 | $1.13M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | $300.00K 10-Q · filed 2023-08-08 | $534.00K 10-Q · filed 2023-08-08 | $834.00K derived: sum of 3 quarters · filed 2024-02-26 | $1.13M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | $267.00K 10-Q · filed 2023-05-08 | $534.00K derived: sum of 2 quarters · filed 2024-02-26 | $834.00K derived: sum of 3 quarters · filed 2024-02-26 | $1.13M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2021-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $567.00K derived: sum of 2 quarters · filed 2024-02-26 | $867.00K derived: sum of 3 quarters · filed 2024-02-26 | $1.07M 10-K · filed 2024-02-26 | |
| 2021-09-30 | $300.00K 10-Q · filed 2022-11-07 | $600.00K derived: sum of 2 quarters · filed 2022-11-07 | $802.00K 10-Q · filed 2022-11-07 | $1.13M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $300.00K 10-Q · filed 2022-08-09 | $535.00K 10-Q · filed 2022-08-09 | $834.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.13M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $267.00K 10-Q · filed 2022-05-09 | $534.00K derived: sum of 2 quarters · filed 2023-02-27 | $834.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.13M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2020-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $567.00K derived: sum of 2 quarters · filed 2023-02-27 | $867.00K derived: sum of 3 quarters · filed 2023-02-27 | $1.07M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $300.00K 10-Q · filed 2021-11-10 | $600.00K derived: sum of 2 quarters · filed 2021-11-10 | $801.00K 10-Q · filed 2021-11-10 | $1.13M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-06-30 | $300.00K 10-Q · filed 2021-08-11 | $534.00K 10-Q · filed 2021-08-11 | $834.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.13M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $267.00K 10-Q · filed 2021-05-10 | $534.00K derived: sum of 2 quarters · filed 2022-02-28 | $834.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.13M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $567.00K derived: sum of 2 quarters · filed 2022-02-28 | $867.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.07M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $300.00K 10-Q · filed 2020-11-12 | $600.00K derived: sum of 2 quarters · filed 2020-11-12 | $802.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $300.00K 10-Q · filed 2020-08-10 | $534.00K 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $267.00K 10-Q · filed 2020-05-14 | ||||
| 2018-12-31 | $198.00K 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |